Janus Kinase Inhibitors: all 1,428 studies that test it

Page 12 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisTerminatedNCT04480086Phase 1
• Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19TerminatedNCT04477993Phase 2/3
• Tofacitinib in Hospitalized Patients With COVID-19 PneumoniaCompletedNCT04469114Phase 3
• Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingNCT04468984Phase 3
• Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging StudyCompletedNCT04468425Phase 1
• Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid ArthritisStatus unknownNCT04464642Phase 4
• Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisActive, not recruitingNCT04454658Phase 1
• Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic LeukemiaStatus unknownNCT04446806Phase 4
• A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingNCT04446650Phase 1/2
• Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot StudyCompletedNCT04431895Early Phase 1
• A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseStatus unknownNCT04424056Phase 3
• Ruxolitinib in the Treatment of Covid-19Status unknownNCT04414098Phase 2
• Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care TherapyWithdrawnNCT04412252Phase 2
• PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release FormulationCompletedNCT04403776Phase 1
• COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19CompletedNCT04403243Phase 2
• Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic TrialStatus unknownNCT04399798Phase 2
• Low Dose Ruxolitinib in Combination With MethylprednisoloneCompletedNCT04397367Phase 1/2
• Baricitinib Compared to Standard Therapy in Patients With COVID-19Status unknownNCT04393051Phase 2
• Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.CompletedNCT04390776Phase 1
• mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Status unknownNCT04390464Phase 4
• TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial PneumoniaStatus unknownNCT04390061Phase 2
• Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisActive, not recruitingNCT04384692Phase 2
• Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19TerminatedNCT04373044Phase 2
• Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib CreamCompletedNCT04361136Phase 1
• Baricitinib Therapy in COVID-19CompletedNCT04358614Phase 2/3
• A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.CompletedNCT04355845Phase 1
• Ruxolitinib to Combat COVID-19WithdrawnNCT04354714Phase 2
• First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19CompletedNCT04350736Phase 1
• Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.CompletedNCT04348695Phase 2
• Safety and Efficacy of Ruxolitinib for COVID-19WithdrawnNCT04348071Phase 2/3
• A Phase II Study in Patients With Alopecia AreataCompletedNCT04346316Phase 2
• Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Status unknownNCT04346147Phase 2
• Safety and Efficacy of Baricitinib for COVID-19WithdrawnNCT04340232Phase 2/3
• A Study of TQ05105 Tablets in Subjects With Myeloproliferative NeoplasmsCompletedNCT04339400Phase 1
• Ruxolitinib in Covid-19 Patients With Defined HyperinflammationCompletedNCT04338958Phase 2
• Treatment of SARS Caused by COVID-19 With RuxolitinibCompletedNCT04334044Phase 1/2
• A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid ArthritisCompletedNCT04333771Phase 3
• TOFAcitinib in SARS-CoV2 PneumoniaStatus unknownNCT04332042Phase 2
• Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 PneumoniaTerminatedNCT04331665Not applicable
• A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）Status unknownNCT04326348Phase 1
• Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsActive, not recruitingNCT04321993Phase 2
• Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.Status unknownNCT04320277Phase 2/3
• Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung DiseaseTerminatedNCT04311567Phase 4
• Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female SubjectsCompletedNCT04309643Phase 1
• A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult ParticipantsCompletedNCT04305899Phase 1
• Efficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsStatus unknownNCT04299971Phase 4
• Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic ImpairmentCompletedNCT04293029Phase 1
• Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHDTerminatedNCT04269850Phase 1/2
• Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive SteroidsCompletedNCT04267250Phase 1
• Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600CompletedNCT04266509Phase 1
• Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCompletedNCT04249284Phase 1
• Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantTerminatedNCT04239989Phase 1
• Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and MetforminCompletedNCT04231435Phase 1
• A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host DiseaseTerminatedNCT04220632Phase 1/2
• Actuate 1901: 9-ING-41 in MyelofibrosisCompletedNCT04218071Phase 2
• A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative ColitisWithdrawnNCT04209556Phase 2
• JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIMCompletedNCT04208464Phase 2
• A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Phase 3
• SHR0302 and Steroid As First Line Therapy for Chronic GVHDCompletedNCT04146207Early Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsCompletedNCT04143477Phase 1
• Tofacitinib in Depression (TIDE)TerminatedNCT04141904Phase 1/2
• A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female ParticipantsCompletedNCT04134715Phase 1
• Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT04131738Phase 1
• Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationWithdrawnNCT04127721Phase 2
• Ruxolitinib as a Salvage Therapy for Hemophagocytic LymphohistiocytosisStatus unknownNCT04120090Phase 3
• A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.CompletedNCT04111614Phase 1
• Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With VitiligoCompletedNCT04103060Phase 2
• Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy ParticipantsCompletedNCT04099563Phase 1
• A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667CompletedNCT04097938Phase 1
• Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male VolunteersCompletedNCT04092712Phase 1
• A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy ParticipantsCompletedNCT04092595Phase 1
• A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy ParticipantsCompletedNCT04090047Phase 1
• A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)Active, not recruitingNCT04088396Phase 3
• An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.CompletedNCT04086719Phase 1
• Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host DiseaseTerminatedNCT04070781Phase 1
• A Study to Determine the Pharmacokinetic Profile of BMS-986165 TabletsCompletedNCT04065932Phase 1
• Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvementStatus unknownNCT04062695Phase 2
• First Line Therapy for High Risk Acute GVHDCompletedNCT04061876Phase 2
• A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy ParticipantsCompletedNCT04055506Phase 1
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmActive, not recruitingNCT04041050Phase 1
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisCompletedNCT04036435Phase 3
• BAriCitinib Healing Effect in earLy pOlymyalgia RheumaticaCompletedNCT04027101Phase 2
• CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnNCT04021082Phase 2/3
• Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive SteroidsCompletedNCT04018274Phase 1
• Dual PD-1 and JAK2 Inhibition in Hematological MalignanciesWithdrawnNCT04016116Phase 2
• Bioavailability Study of PF-06651600 Formulations in Healthy ParticipantsCompletedNCT04004663Phase 1
• Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaCompletedNCT03989466Phase 1
• Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT03983239Phase 1
• A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentCompletedNCT03983161Phase 1
• A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy ParticipantsCompletedNCT03979248Phase 1
• Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese SubjectsCompletedNCT03956953Phase 1
• Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male SubjectsCompletedNCT03945760Early Phase 1
• Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165CompletedNCT03930602Phase 1
• Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.CompletedNCT03929510Phase 1
• A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic DermatitisCompletedNCT03920852Phase 1
• PF-06651600 Taste Study.CompletedNCT03916393Phase 1
• Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy ParticipantsCompletedNCT03916250Phase 1
• Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareCompletedNCT03910543Phase 1
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataActive, not recruitingNCT03898479Phase 2/3
• An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver DamageCompletedNCT03890809Phase 1

← Janus Kinase Inhibitors overview